HSCSW (HeartSciences) Debt-to-Revenue : N/A (As of Apr. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HSCSW HeartSciences Inc HSCSW
18 GF Score
Price $0.08
! 10 Warning Signs
View Full Analysis

What is HeartSciences Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

HeartSciences's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Apr. 2026 was $3.76 Mil. HeartSciences's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Apr. 2026 was $0.18 Mil. HeartSciences's annualized Revenue for the quarter that ended in Apr. 2026 was $0.00 Mil.

HeartSciences Debt-to-Revenue Historical Data

* Premium members only.

The historical data trend for HeartSciences's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

HeartSciences Debt-to-Revenue Chart

HeartSciences Annual Data
Trend Apr20 Apr21 Apr22 Apr23 Apr24 Apr25 Apr26
Debt-to-Revenue
Get a 7-Day Free Trial 440.21 313.20 54.53 746.50 984.25

HeartSciences Quarterly Data
Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26 Apr26
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 186.63 243.38 109.50 N/A N/A

HSCSW vs IRIX, ALRTF, ADGM: Debt-to-Revenue Comparison

For the Medical Devices subindustry, HeartSciences's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

HeartSciences Debt-to-Revenue vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, HeartSciences's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where HeartSciences's Debt-to-Revenue falls into.


HSCSW
18GF Score
HeartSciences Inc HSCSW
Debt-to-Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

HeartSciences Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

HeartSciences's Debt-to-Revenue for the fiscal year that ended in Apr. 2026 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(3.761 + 0.176) / 0.004
=984.25

HeartSciences's annualized Debt-to-Revenue for the quarter that ended in Apr. 2026 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(3.761 + 0.176) / 0
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Apr. 2026) Revenue data.

HeartSciences Business Description

Other Exchanges HSCS:USA
Address 550 Reserve Street, Suite 360, Southlake, TX, USA, 76092
HeartSciences Inc is an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease. Its objective is to improve healthcare by making it a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. It is developing a suite of AI-ECG diagnostic solutions for use in any healthcare care setting, either via MyoVista Insights cloud-platform using one of the millions of ECG devices currently in clinical use or via MyoVista wavECG Device.
18GF Score

Get the complete analysis for HSCSW

Debt-to-Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.08
Price